Organogenesis (ORGO) for enzymatic debridement of severe burns and chronic wounds.

A niche biopharma like Regeneron (REGN), but focused on developing unique tissue repair solutions.

• NexoBrid: A biopharmaceutical product for the removal of eschar (dead or damaged tissue) in adults with deep partial- and full-thickness thermal burns.
• EscharEx: A product in development for the debridement of chronic and other hard-to-heal wounds.
• MW005: A product in development for the treatment of low-risk basal cell carcinoma.

MediWound (MDWD) sells primarily to other companies and institutions within the healthcare sector. Its major customers include:

• Burn centers
• Hospitals burn units

Mr. Ofer Gonen has over 20 years of executive management and corporate development experience in the biopharmaceutical industry. Prior to joining MediWound, he served as the CEO of Clal Biotechnology Industries (TASE: CBI) and was a managing partner at the Anatomy Medical Technology Fund. He is also a co-founder of Cactus Acquisition Corp. 1 (Nasdaq: CCTS) and ARTE Venture Group. Mr. Gonen has held board positions at several leading life sciences companies, including Gamida Cell (Nasdaq: GMDA) and Anchiano Therapeutics (Nasdaq: ANCN), and served on the boards of Colbar and Cadent, both of which were successfully acquired by Johnson & Johnson and Novartis, respectively. He is skilled in entrepreneurship, global strategic partnerships, IPOs, licensing deals, and M&A transactions.

Ms. Hani Luxenburg brings over 20 years of experience in financial leadership, strategic planning, and operational management. She possesses extensive expertise in scaling organizations, optimizing financial performance, and advancing corporate strategy within the life sciences and technology sectors. Before her role at MediWound, Ms. Luxenburg served as Chief Financial Officer of BIRD Aerosystems and held senior finance positions at AstraZeneca, Alvarion Technologies Ltd., and Ernst & Young.

Dr. Shmulik Hess has over two decades of expertise in drug development and commercial operations within the healthcare sector. Prior to joining MediWound, he served as CEO at Tabby Therapeutics, Enlivex Therapeutics (Nasdaq: ENLV), and Valin Technologies. He also held a global operations executive role at SciGen Ltd., which was acquired by VBI Vaccines.

Dr. Ety Klinger served as Vice President of R&D at Proteologics Ltd. before joining MediWound, where she led discovery projects in collaboration with GlaxoSmithKline and Teva. She spent 17 years in leadership positions within Teva's global innovative R&D division and played a pivotal role in the development of Copaxone® for multiple sclerosis.

Mr. Barry Wolfenson co-founded vTail Healthcare Telecommunications, a healthcare-wide digital platform. He also served as a Strategic Advisor to Origin, Inc. on their Phase III-ready IonoJet™ technology. Mr. Wolfenson is currently on the Board of Directors at SANO Diagnostics, having previously served as its CEO, and spent 13 years at Derma Sciences.

The key risks for MediWound (MDWD) primarily stem from the inherent challenges of the biopharmaceutical industry, particularly concerning product development, regulatory hurdles, and market adoption.

1. Clinical Trial Outcomes and Regulatory Approval for Pipeline Products: MediWound's future growth and financial performance heavily depend on the successful completion of clinical trials and subsequent regulatory approvals for its pipeline products, especially EscharEx, which is in Phase III development for chronic and hard-to-heal wounds, and MW005 in Phase I/II for basal cell carcinoma. The product development process is inherently uncertain, lengthy, and expensive. Any delays, negative results, or failures in clinical studies, or an inability to obtain necessary marketing approvals from regulatory bodies such as the FDA and EMA, would significantly impede the company's growth trajectory and could negatively impact investor sentiment.
2. Commercialization, Market Acceptance, and Competition: Even with regulatory approval, there is a substantial risk associated with the commercial success and market adoption of MediWound's products, including its lead product, NexoBrid, and future pipeline candidates. Factors such as physician and burn center acceptance, competition from existing or new treatments, pricing pressures, and adequate reimbursement policies are critical. The company's ability to effectively penetrate markets, maintain strong intellectual property protection, and manage its reliance on third-party partners for commercialization also poses significant challenges.
3. Financial and Operational Stability: While MediWound has demonstrated a strong balance sheet and cash runway in some recent reports, the company operates in a capital-intensive industry, and the need for additional financing is a recurring risk mentioned in its forward-looking statements. Economic headwinds, including concerns about healthcare expenditure, could impact MediWound's financial health and its ability to fund ongoing research and development as well as commercialization efforts. Furthermore, the company faces operational risks related to manufacturing, including the ability to scale production, satisfy demand, and maintain compliance with stringent good manufacturing practice (cGMP) regulations. Dependence on contracts with governmental agencies, such as BARDA, also represents a potential operational and financial dependency.

The addressable markets for MediWound's main products are as follows:

• NexoBrid: The total addressable market for NexoBrid in the United States for severe burns is estimated at approximately $300 million. NexoBrid is approved in over 40 countries, including the U.S., European Union, and Japan.
• EscharEx: The addressable U.S. debridement market that EscharEx targets is estimated to exceed $2.5 billion. MediWound also notes the chronic wound opportunity, which EscharEx aims to address, is materially larger than the burns market, with one source indicating a $4 billion chronic wound market. Expected peak U.S. sales for EscharEx are estimated at approximately $831 million across venous leg ulcer (VLU) and diabetic foot ulcer (DFU) indications.
• MW005 (Basal Cell Carcinoma): The global basal cell carcinoma treatment market was valued at approximately USD 2.96 billion in 2023 and USD 5.5 billion in 2024, with projections to reach around USD 9.97 billion by 2035. North America held a significant share of this market, accounting for approximately 60% in 2025. The North America basal cell carcinoma treatment market is expected to reach USD 5.6 billion by the end of 2032.

Here are 3-5 expected drivers of future revenue growth for MediWound (MDWD) over the next 2-3 years:

1. Expanded NexoBrid Manufacturing Capacity and Regulatory Approvals: MediWound has commissioned an expanded NexoBrid manufacturing facility, increasing its production capacity sixfold. Regulatory approvals for commercial output from this new facility are anticipated in the second half of 2026, which is crucial for meeting global demand and supporting current and future contracts. This increased capacity is expected to alleviate prior supply constraints and drive sales.
2. Growing NexoBrid Commercial Adoption and Government Contracts: Continued adoption of NexoBrid in burn centers, with the product already in over 70 U.S. burn centers, is a key growth driver. Furthermore, securing new and sustained support from government entities like the U.S. Biomedical Advanced Research and Development Authority (BARDA) and the Department of War through contracts for stockpiling, development of a room-temperature stable formulation, and blast-injury applications are vital for revenue.
3. EscharEx Clinical Development and Expansion into New Indications: The ongoing global Phase III VALUE trial for EscharEx in venous leg ulcers (VLUs) is a significant catalyst, with an interim assessment and completion of enrollment projected by year-end 2026. Beyond VLUs, MediWound plans to expand the EscharEx clinical program into diabetic foot ulcers (DFUs) and pressure ulcers (PUs), with Phase II and investigator-initiated studies expected to commence in the second half of 2026, significantly broadening its addressable market. An initial revenue contribution from EscharEx is projected in the 2028 outlook, pending regulatory approval.
4. Strategic Partnerships for EscharEx: MediWound is strengthening its EscharEx program through collaborations with leading advanced wound care companies. A new research collaboration with B. Braun for the EscharEx DFU Phase II study, alongside existing partnerships, indicates strong industry validation and potential for enhanced commercialization strategies upon approval.

Share Issuance

• In 2025, MediWound completed a $30.0 million registered direct offering of ordinary shares and received $3.5 million in proceeds from Series A warrant exercises. The company plans to use the net proceeds to primarily support EscharEx's pre-commercial activities, enhance large-scale manufacturing capabilities, and for general corporate purposes.
• In 2024, MediWound completed a $25 million private investment in public equity (PIPE) offering, with Mölnlycke Health Care leading with a $15 million investment. These funds were intended to advance EscharEx pre-commercial activities, expedite the development of large-scale manufacturing capabilities for EscharEx, and support general corporate purposes.
• In February 2023, MediWound announced a $27.5 million registered direct offering of ordinary shares. The net proceeds from this offering were primarily designated for accelerating the development of EscharEx, establishing a U.S. commercial presence, supporting business development activities, and for general corporate purposes.
• In September 2022, MediWound conducted a registered direct offering with expected gross proceeds of approximately $13.26 million and a private investment in public equity (PIPE) offering with expected gross proceeds of approximately $17.24 million.

Inbound Investments

• MediWound has secured significant non-dilutive funding through government collaborations, including $120 million from the Biomedical Advanced Research and Development Authority (BARDA) for the development, manufacturing, and procurement of NexoBrid under a Project BioShield contract.
• In 2024, Mölnlycke Health Care made a strategic $15 million investment in MediWound as part of a $25 million private placement financing, which was accompanied by a collaboration agreement.
• In 2025, MediWound received a €2.5 million grant from the European Innovation Council to further the development of EscharEx.

Capital Expenditures

• During the first half of 2025, MediWound incurred $2.3 million in capital expenditures, which were primarily directed towards manufacturing scale-up.
• The company is actively enhancing its large-scale manufacturing capabilities, highlighted by the operational launch of an expanded NexoBrid manufacturing facility in 2025, with regulatory approvals for commercial output anticipated in 2026. This expansion is expected to result in a sixfold increase in production capacity.